Clinical Trial Update: Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC [Phase 1]

View source ↗

Summary

Phase 1 study evaluating toripalimab with anlotinib and SBRT for untreated brain metastases in gene-negative non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Hubei Cancer Hospital | Conditions: NSCLC | Phase 1 | Status: COMPLETED